It would extend beyond merely expanding patient access to treatment, enabling the government to prevent misuse and ensure safety through systematic monitoring and oversight
It is a growth hormone secretagogue
Mechanisms of action of Semaglutide is a GLP-1 receptor agonist that works by stimulating insulin secretion and reducing glucagon production
5/5 mg vial + 2 mL BAC water: Concentration = 2,500 mcg BPC-157 + 2,500 mcg TB-500 per mL 250 mcg dose (of each) = 10 units (0.1 mL) on a 100-unit insulin syringe 500 mcg dose (of each) = 20 units (0.2 mL) on a 100-unit insulin syringe Doses per vial: 20 doses at 250 mcg each, or 10 doses at 500 mcg each Supplies Needed (4-Week Loading at 500 mcg/day) 3 vials BPC-157/TB-500 blend (5/5 mg each) provides 30 doses at 500 mcg, covers 28 days with margin 3 vials bacteriostatic water (30 mL each) 30 insulin syringes (2931 gauge, 100-unit) Alcohol prep pads Administration Injection Technique Standard subcutaneous injection
The SUSTAIN 1 trial [166] (ClinicalTrials.gov identifier: NCT02054897) was a 30- week, double-blind, randomised, parallel-group, placebo-controlled trial of once-weekly subcutaneous semaglutide 0.5 mg, or semaglutide 1 mg compared with placebo in treatment-naive patients with type 2 diabetes
Beyond Skin: The Longevity Connection Early research hints that GHK-Cu may influence more than just skin: Reduces inflammation in colitis models Promotes nerve and tissue regeneration Supports mitochondrial and antioxidant pathways in aged tissues GHK-Cu isnt just cosmetic its a cellular reset signal that bridges the gap between beauty and longevity
